News

Zacks Investment Research on MSN1d
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...
Asian News International on MSN4d
Lilly's orforglipron consistent with injectable GLP-1 medicines in Phase 3 trial
Eli Lilly and Company announced on Friday positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy ...
Becker's Hospital Review5d
Eli Lilly’s 1st GLP-1 pill shows favorable results in late-stage trial
Eli Lilly completed a phase 3 trial for its weight loss drug, orforglipron, which showed promising results in evaluating its safety and efficacy for adults with Type 2 diabetes and inadequate glycemic ...
pharmaphorum5d
Lilly soars on first data for oral obesity candidate
Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...
GEN - Genetic Engineering and Biotechnology News2d
StockWatch: Investors Hungry for Lilly after Diabetes Pill Aces Phase III Trial
Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...
BenefitsPRO4d
Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic
Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...
BioSpace5d
Lilly Skyrockets on ‘Injectable-Like Efficacy’ for Oral GLP-1 in Phase III Diabetes Trial
Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...
CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions
The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemesThe trial is expected to ...
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ...
American Association of Individual Investors5d
Why Structure Therapeutics Inc.’s (GPCR) Stock Is Up 29.14%
Structure Therapeutics Inc.’s GPCR share price has surged by 29.14%, which has investors questioning if this is right time to sell.
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...